发明名称 |
PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER |
摘要 |
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease. |
申请公布号 |
US2017000896(A1) |
申请公布日期 |
2017.01.05 |
申请号 |
US201615270542 |
申请日期 |
2016.09.20 |
申请人 |
Immunomedics, Inc. |
发明人 |
Govindan Serengulam V.;McBride William J.;Sathyanarayan Nalini;Mazza-Ferreira Christine;Goldenberg David M. |
分类号 |
A61K47/48;C07K16/10;C07K16/28;A61K45/06;C07K16/30 |
主分类号 |
A61K47/48 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating cancer comprising administering to a subject with cancer an antibody or antigen-binding antibody fragment that binds to a tumor-associated antigen (TAA), wherein the antibody or antigen-binding antibody fragment is conjugated to pro-2-pyrrolinodoxorubicin (P2PDox), wherein the antibody comprises human constant regions selected from the group consisting of IgG1, IgG2, IgG3 and IgG4. |
地址 |
Morris Plains NJ US |